VedaLab key facts
as of Oct 2026- Developer and manufacturer of rapid medical diagnostic tests and kits in Alençon, France.
- VedaLab is valued at approximately $137.5M as of Oct 2026 (last reported valuation).
- It has raised $12.1M; the latest was PE Growth/Expansion in Jan 2025.
- Notable investors include Turenne Groupe, Sodero.
- Status: Privately Held (backing).
VedaLab's last reported valuation, Sep 2014. Nothing priced has surfaced since.
- ·Watch VedaLab: the Monday email on marks, rounds and moves
VedaLab funding rounds
No funding rounds for VedaLab are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs VedaLab
2VedaLab valuation
VedaLab's last reported valuation was $138 million in Sep 2014. No priced round, secondary trade or fund mark has surfaced since.
VedaLab investors
2 investors are on record for VedaLab, including Turenne Groupe and Sodero. By type, the record holds 1 venture capital firm and 1 private equity firm.
About VedaLab
Developer and manufacturer of rapid medical diagnostic tests and kits in Alençon, France. The company specializes in research and development and the production of rapid immunochromatographic tests and kits for the human healthcare, veterinary, agribusiness and environmental diagnostic sectors.
- Sector
- Healthcare
- HQ
- Alencon, France
- Founded
- 1991
- Employees
- 50
- Website
- vedalab.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.